HEALTH PROFESSIONAL · SOURCE READING

AKT inhibitor therapy

Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 25, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Metastatic Breast Cancer / Metastatic HER2-Negative Hormone Receptor–Positive Breast Cancer

Activating AKT1 variants are found in 5% to 10% of advanced breast cancers. AKT is downstream from both PIK3CA and PTEN in the PIK3CA/AKT/PTEN pathway.

Continue within this section

Capivasertib →

Preserved source evidence · Not medical advice